Introduction {#Sec1}
============

There has been significant progress in the operative management of breast carcinoma within the last six decades, as demonstrated by the adoption of conservative breast cancer surgery with great enhancements in early and delayed breast reconstruction surgery into skin-sparing mastectomy, which maintains an original skin cover and has already gained broad approval \[[@CR1], [@CR2]\].

Despite this progress, conventional skin-sparing mastectomy forfeits both the nipple and the areola, which serve as a focus of the breast \[[@CR2]\]. The nipple-areola complex (NAC) provides unique character because many women believe that their own breast renovation is not complete until the nipple is reassembled \[[@CR3]\]. Nonetheless, nipple renovation rarely provides patient satisfaction because of insufficient projection, colour, form, sizing, texture, consistency and posture \[[@CR4], [@CR5]\].

Nonetheless, nipple renovation rarely provides patient satisfaction because of insufficient projection, colour, form, sizing, texture and consistency and posture \[[@CR6]\].Also Nipple reconstruction is at risk of tissue necrosis as the tissue becomes critically ischemic when raised off the skin blood supply. Skin perfusion is related to microcirculation \[[@CR7]\] As such, nipple-sparing mastectomy (NSM) has gained consideration for the purpose of achieving 3 main targets: first, oncological safety; second, nipple-areola viability; and third, improved outcome \[[@CR8]\]. By far, the most crucial of these aims is to achieve oncological safety because the nipple is linked to the mammary gland through lactiferous ducts and is likely at risk for malignant locoregional recurrence.

Recent multivariate models that can help the selection of patients eligible for NSM have revealed the following predictors of occult nipple involvement: tumour size, tumour location and tumour-nipple distance \[[@CR9]\].

Patients and methods {#Sec2}
====================

Study design {#Sec3}
------------

A retrospective observational study that took place at the Surgical Oncology Unit of the Department of Surgery, Suez Canal University Hospital, from June 15, 2014 to January 25, 2017 assessing the prevalence of malignant affection of the nipple-areola complex (NAC) in breast carcinoma patients and its correlation with prognostic factors for breast cancer. This research project has been approved by the research ethics committee of the Faculty of Medicine, Suez Canal University (reference number \#1890.

Study population {#Sec4}
----------------

The study included One hundred thirty-seven (137) women with a diagnosis of operable breast cancer who underwent modified radical mastectomy. We excluded patients with clinical involvement of the NAC, such as Paget's disease, fixed nipple, and nipple erosion or induration, scheduled for other simultaneous procedure, had recurrent breast cancer patient, with previous radiation over chest wall, who cannot understand or cannot accept the study (refused to sign written informed consent) or patient unfit for surgery. Written consent was obtained from all patients.

Study hypothesis {#Sec5}
----------------

We hypothesized that nipple- sparing mastectomy can be performed in certain selected patients with oncological safety and better cosmetic outcome.

Study outcome {#Sec6}
-------------

The primary outcome was to identify the subtle group of patients whom will have a privilege of NAC-sparing mastectomy.The secondary outcome of this study was to correlate between NAC involvement and certain tumor factors including tumor size, tumor--NAC distance, histological type, nuclear grade of the tumor and axillary lymph node status.

Preoperative workup and surgical procedure {#Sec7}
------------------------------------------

All patients provided a full history and underwent general and local clinical examinations, pre-operative laboratory tests, and radiological and pathological evaluations, pre-operative needle biopsy, either fine-needle aspiration biopsy (FNAB) or Tru-Cut core needle biopsy guided by ultrasonography.

Study intervention and surgical procedure {#Sec8}
-----------------------------------------

The nipple and areola were segregated from the breast tissue and then sectioned at 5-mm intervals from the core of the nipple to the edge. Each section was further sectioned at 2.5 mm and embedded for assessment of its entirety. Specimens were examined histopathologically, as follow: Tumor size, type, and grade, Lymph node involvement, number of involved lymph nodes, tumor stage, and NAC involvement, as indicated by malignant cells. Malignant NAC involvement was examined in detail, including in terms of the distance from the periphery of the main tumour. All patients enrolled in this study were managed by modified radical mastectomy. The breast tissue was removed, and formal axillary lymph node dissection was performed through an elliptical incision encompassing the NAC. All breast tissue and axillary lymph nodes were removed en bloc, followed by histopathological examination.

Statistical analysis {#Sec9}
--------------------

SPSS version 20 (IBM) was used for the data analysis; 95% confidence intervals (CIs) were calculated, and *p* values \< 0.05 were considered statistically significant. Data. Mann Whitney was used for non-normally distributed data of quantitative variables. Fischer exact test was used to compare between data of qualitative nominal variables. Wilcoxon sign test was used compare between data of qualitative categorical variables. Relative Risks (RRs) with 95% confidence intervals (CIs) had been estimated from the novel publications. To measure the pooled RRs with 95% CIs, fixed-effect model was used when there was minimal heterogeneity in the variables among studies and random-effect-model when significant heterogeneity. Between-study, chi-square test was used for presenting heterogeneity of RR. Chi Square test was considered significant if p\<0.05. ROC curve analysis was performed to identify a cut-off value for the tumour-nipple distance associated with NAC involvement.

Results {#Sec10}
=======

In the present study, 137 female patients with breast cancer were included. They were classified after mastectomy into 2 subgroups according to NAC involvement. Demographic and clinicopathological data for all patients are shown in Table [1](#Tab1){ref-type="table"}. The upper outer compartment was the most common tumor site in all patients (37.2%). Regarding histopathology, the most common type of all recruited patients was invasive ductal carcinoma (IDC, 75.2%), followed by infiltrating lobular carcinoma (ILC, 24.2%), with 46% of the patients having histological grade Ι disease. Lymph node involvement was present in 28.5% of all patients. Stage ΙΙ disease was present in the majority of cases (58.4%). Lymphovascular invasion was revealed in 15.3% of the patients Fig [1](#Fig1){ref-type="fig"}.Table 1Demographic and clinicopathologic data of all patientsAll patientsPatients with NAC\
*N* = 12Patients without NAC\
*N* = 125*p*-valueAge47.39 ± 8.0150.9 ± 6.847.1 ± 8.10.136 ^a^32--58Age subgroups30--3935 (25.5)2 (16.7)33 (26.4)0.686 ^b^40--4937 (27)3 (25)34 (27.2)≥ 5065 (47.4)7 (58.3)58 (46.4)Tumor size2.9 ± 1.164.18 ± 1.162.35 ± 1.1\<0.001 ^a^Range1--6\<  4 cm101 (73.7)4 (33.3)97 (77.6)0.003 ^b^≥ 4 cm36 (26.3)8 (66.7)28 (22.4)Tumor nipple distance3.38 ± 0.921.95 ± 0.723.52 ± 0.84\<0.001^a^Range1.4--6\<  2 cm6 (4.4)4 (33.3)2 (1.6)\<0.001 ^ɑ^2 -- \< 2.5 cm11 (8)2 (16.7)9 (7.2)2.5 - \<  3 cm4 (2.9)3 (25)1 (0.8)3 - \<  4 cm79 (57.7)1 (8.3)78 (62.4)≥ 4 cm37 (27)2 (16.7)35 (28)Tumor siteUpper inner22 (16.1)1 (8.3)21 (16.8)0.470 ^b^Upper outer26 (19.1)2 (16.7)24 (19.2)Lower inner31 (22.6)1 (8.3)30 (24)Lower outer7 (5.1)1 (8.3)6 (4.8)Central51 (37.2)7 (58.3)44 (35.2)Histologic typeDCIS32 (23.4)5 (41.7)27 (21.6)0.033 ^b^IDC37 (27)5 (41.7)32 (25.6)LCIS43 (31.4)1 (8.3)42 (33.6)ILC25 (18.2)1 (8.3)24 (19.2)histologic gradeGrade I63 (46)2 (16.7)61 (48.8)0.003 ^b^Grade II39 (28.5)2 (16.7)37 (29.6)Grade III35 (25.5)8 (66.7)27 (21.6)Lymph node involvementPositive39 (28.5)9 (75)30 (24)0.001^b^Lymph node numbers\<  413 (9.5)0 (8.3)13 (43.3)\<0.001 ^ɑ^4 - \< 1014 (10.2)1 (11.1)13 (43.3)≥ 1012 (8.8)8 (88.9)4 (13.3)StagingII80 (58.4)3 (27.3)77 (61.6)0.032 ^b^III57 (41.6)8 (72.7)49 (38.9)Multifocal tumor13 (9.5)4 (33.3)9 (7.2)0.016 ^b^Multicenteric14 (10.2)5 (41.7)9 (7.2)0.003 ^b^Lymphovascular invasion21 (15.3)5 (41.7)16 (12.8)0.020 ^b^Estrogen receptor status13 (9.5)6 (50)7 (5.6)\<0.001^b^Progesterone receptor status12 (8.8)7 (58.3)5 (4)\<0.001^b^HER status17 (12.4)7 (58.3)10 (8)\<0.001^ba^:Mann Whitney test ^b^: Fischer exact test ^ɑ^: Wilcoxon sign testFig. 1Invasive ductal carcinoma of no special type surrounding the smooth muscle bundles of the nipple-areola complex (100X) (**a**). Higher magnification of (**a**) (200X) (**b**). Invasive lobular carcinoma surrounding the smooth muscle bundles of the nipple-areola complex (100X) (**c**). Distribution of the tumour types included in the study in relation to nipple-areola complex involvement (**d**)

While comparing the subgroups regarding age revealed no significant differences, patients with NAC involvement showed significantly larger tumors and shorter tumor-nipple distances than patients without NAC involvement. There was no difference in the tumor site between the subgroups. There were no significant differences between the subgroups regarding the histological type; however, regarding the histological grade, grade ΙΙΙ disease was significantly more frequent among the patients with NAC involvement.

Lymph node involvement was significantly more common in the NAC group, as more than 10 lymph nodes were excised from approximately 89% of patients in this subgroup compared to 13.3% of patients in the other subgroup. Stage ΙΙΙ disease was found in 72.7% of patients with NAC involvement compared to 38.9% of patients without NAC involvement (*p* = 0.032). Multicentric and multifocal tumors were detected significantly more frequently among patients with NAC involvement (*p* = 0.016 and 0.003, respectively), as was lymphovascular invasion, which was found in 41.7% of patients with NAC involvement compared to 12.8% of patients without NAC involvement. A significant number of patients with NAC involvement were ER- and PR-, but a higher percentage of patients in this group than in the other group were HER+.

Age was not a significant predictor of NAC involvement. The risk of NAC increased with tumor sizes ≥4 cm compared to tumor sizes \< 4 cm (RR = 6.92, *p* = 0.003). Tumor-nipple distances \< 2 cm versus \> 2 cm and \<  2.5 cm versus \> 2.5 cm carried a greater risk of NAC involvement Relative Risk (RR) =0.029 and 0.019; *p* = 0.002 and 0.004, respectively) Table [2](#Tab2){ref-type="table"}.Table 2Predictors of NAC involvementRRCI (95%)Waldp-valueLowerupperAge subgroups\< 40 versus \> 40 years1.990.39110.140.6870.407\> 40 versus \> 50 years1.360.3325.640.1880.665Tumor size\
\<  4 versus ≥ 4 cm6.921.9424.178.890.003Tumor nipple distance\
\<  3 cm\< 2 versus \> 2 cm0.0290.0030.2629.880.002\< 2.5 versus \> 2.5 cm0.0190.0010.2768.420.004\<  3 versus \> 3 cm0.2570.0322.081.610.203\<  4 versus \> 4 cm4.450.39150.791.440.229Lymph node metastasisMetastasis versus no metastasis9.52.4137.3710.37\<0.001≥ 10versus \< 1026.002.45275.827.310.007Multifocal tumorMultifocal versus not multifocal6.441.6225.587.010.008MulticentericMulticentric versus not multicentric9.202.4234.9110.65\<0.001Lymphovascular invasionInvasion versus noninvasion4.861.3717.186.040.014Estrogen receptor statusER - versus ER+16.854.3065.9716.46\<0.001Progesterone receptor statusPR - versus PR+33.607.84143.9722.40\<0.001HER statusHER + versus HER -16.04.3160.0917.10\<0.001Staging IIIStage III versus II4.191.116.564.170.041Histologic tumor typeDCIS versus ILC0.2250.0252.061.740.187DCIS versus IDC0.2670.0292.431.370.241IDC versus ILC1.750.10529.260.1520.697Histologic gradeGrade III versus grade I9.031.7945.407.140.008Grade III versus grade II5.481.0727.894.200.040

Lymph node metastasis was associated with NAC involvement (RR = 9.5; *p* = 0.001), with increased risk when more than 10 lymph nodes were involved (RR = 26; *p* = 0.007). Lymphovascular invasion was a significant predictor of NAC involvement (RR = 4.86; *p* = 0.014). Multifocal (RR = 6.44; *p* = 0.008) and multicentric (RR = 9.5; p = 0.001) tumors were significantly associated with NAC involvement Table [2](#Tab2){ref-type="table"}.

ER- patients had a higher risk for NAC involvement than ER+ patients (RR = 16.85; *p* \< 0.001). Additionally, PR- patients had a higher risk for NAC involvement than PR+ patients (RR = 33.6; p \< 0.001) Table [2](#Tab2){ref-type="table"}.

HER+ patients were more likely to have NAC involvement than HER- patients (RR = 16.0; p \< 0.001). Stage ΙΙΙ cancer was significantly associated with NAC involvement compared to stage ΙΙ cancer (RR = 4.19; *p* = 0.041) Table [2](#Tab2){ref-type="table"}.

Both histopathological types identified were considered non-predictors for NAC; however, histological grade III disease carried a greater risk than grade I disease of developing NAC involvement (RR = 9.03; *p* = 0.008). Additionally, histological grade III disease carried a greater risk than grade II disease of developing NAC involvement (RR = 5.48; *p* = 0.040) Table [2](#Tab2){ref-type="table"}.

ROC curve analysis was performed to identify a cut-off value for the tumor-nipple distance associated with NAC involvement; a tumor-nipple distance of 2.4 cm had a sensitivity and specificity of 83 and 68%, respectively (AUC = 0.775; *p* = 0.002) Fig. [2](#Fig2){ref-type="fig"}.Fig. 2ROC curve, cutoff value of tumor nipple distance for detecting NAC

Discussion {#Sec11}
==========

NAC resection was previously included in the surgical management of breast carcinoma. This was done regarding the evidence of accumulated lymphatic drainage of the breast into the subareolar Sappey plexus before eventually draining into the axillary lymph nodes \[[@CR10]\]. Turner-Warwick had discarded the previous theory and demonstrated that lymphatic vessels accompany blood vessels in the breast tissue leaving the nipple area \[[@CR11]\]. To clarify this discrepancy, we postulated that Sappey's original studies included lactating but not resting breasts \[[@CR12]\].

In this analysis, we studied surgical specimens from 137 females who had undergone mastectomy. Of all the examined specimens, 12 (8.7%) showed tumour involvement in the NAC. Six decades ago, some authors reported rates of tumor involvement in the NAC higher than that found in this study \[[@CR13]--[@CR15]\]. A relatively high rate of NAC involvement was also documented in a study by Pirozzi et al. \[[@CR16]\]; however, only 50 women were enrolled in their study. Another study reported only 22 cases (16%) of NAC involvement \[[@CR17]\]. A small Libyan study documented NAC involvement in only 3 (12%) out of 25 cases \[[@CR18]\], which is similar to the figure reported by Crowseet et al. \[[@CR19]\], while an Egyptian study demonstrated an incidence rate of 6.3% \[[@CR20]\]. Incidence rates of nipple involvement (NI) ranging from 0 to 58% have been reported recently \[[@CR21]\]; however, that study did not include the areola in the analysis. The anatomical difference between the areola and nipple is that the areola does not contain parenchymal ducts; on the other hand, the nipple has a lining of ductal cells; any of those cells could potentially produce breast cancer.

Many women prefer to preserve the nipple after mastectomy for a better cosmetic outcome. For this reason, multiple studies, including ours, have investigated the differences between breast cancer patients with and without NAC involvement and demonstrated the predictors of NAC involvement to enable the selection of patients who may be candidates for NAC preservation while maintaining oncological safety; however, other studies have shown discrepancies regarding the predictive factors.

In our study, we detected significantly larger tumours with shorter tumour-nipple distances in patients with NAC involvement than in patients without NAC involvement. Patients with a tumour-nipple distance ≤2.5 cm were more likely to have NAC involvement than patients with longer distances; additionally, patients with a tumour size ≥4 cm were at risk for NAC involvement (*p* = 0.003). A large meta-analysis by Zhang et al. reported that tumour-to-nipple distances ≥2.5 cm were associated with a reduced risk of NI \[[@CR22]\]. Other reports have confirmed this distance regarding NI \[[@CR17], [@CR23]\]. Although another study comparing 2 groups regarding NAC involvement revealed no difference according to the tumor-nipple distance (*p* = 0.735), in the same study, when a dichotomous division of the distance was analysed, a distance ≤3 cm was detected in 100% of cases with NAC involvement compared to 60.5% of cases without NAC involvement (*p* = 0.007) \[[@CR16]\]. This finding also agrees with the data reported by Bishop et al. \[[@CR24]\]. A tumour size of more than 5 cm carried an increased risk for NI in a study by Wang et al. \[[@CR25]\]. Pirozzi and his colleagues reported findings consistent with our results with respect to tumour size, as they found no differences between the two studied groups regarding NI when they categorized tumour size as \< 3 or ≥ 3 cm (*p* = 0.693) \[[@CR16]\].

With respect to lymph node metastasis in our analysis, we found a significantly higher rate of lymph node involvement among patients with NAC involvement than those without NAC involvement (9(75%) versus 30(24%), respectively, *p* = 0.001). Additionally, lymphovascular invasion was more prevalent in patients with than in those without NAC involvement (5(41.7%) vs. 16 (12.8%), respectively). Mallon et al. described that nodal involvement was a valuable predictor of NAC involvement \[[@CR26]\]; however, another report revealed contrasting results \[[@CR27]\], in which a higher nodal stage was not associated with NI. The results reported by Wang et al. agree with our findings, as they demonstrated that nodal involvement was associated with NAC involvement (NAC involvement in 14% of tumours positive for nodal involvement vs. 8% in tumour negative for nodal involvement, *p* = 0.0331) \[[@CR25]\].

Despite lymphovascular invasion being an important predictor of increased tumour aggressiveness, the data published by Pirozzi et al. revealed that lymphovascular invasion was detected in 15 of the 50 cases studied; of those patients, 14 did not show NI, and only 1 showed NI. Comparing the two groups showed no significant difference \[[@CR16]\]. The previous results were in contrast with those revealed by Vyas et al. \[[@CR17]\] and Vlajcic et al. \[[@CR28]\], probably owing to the small sample size included in the current study.

Regarding the histological type among our cases, we detected that among all patients, as well as patients with NAC involvement, there was a predominance of IDC over ILC; however, there was no significant difference (*p* = 0.171). Additionally, none of the detected pathological types were significant predictors of NAC involvement (*p* = 0.167). However, the histological grade was considered a significant predictor of NAC involvement among our cases, as 8 (66.7%) of the patients with NAC involvement had grade 3 tumors.

Multiple studies have suggested that NI is associated mainly with ductal carcinoma in situ (DCIS) \[[@CR23], [@CR29]--[@CR31]\]. Li et al. \[[@CR32]\] demonstrated that IDC or IDC with associated DCIS and breast carcinoma with invasive micropapillary carcinoma (IMPC) components were the most common tumour types associated with NI. Contrasting results regarding the histological grade were reported by Pirozzi et al., as they found no significant difference among groups regarding the histological grade \[[@CR16]\]. Other studies have suggested that lobular carcinoma in situ (LCIS) is strongly associated with NI \[[@CR33]\], although others have reported a negative association between LCIS and NI \[[@CR34]\], as LCIS is not considered a true tumor lesion and does not require an additional safety margin when present at the surgical margin \[[@CR35]\].

In our study, there was no significant difference in the tumor site between the groups, meaning that no specific region was associated with NAC involvement. Multiple studies have shown that the tumor location is an important predictor of NAC involvement \[[@CR12], [@CR36], [@CR37]\]. This discrepancy could be attributed to the relatively small sample size, which is also reflected in the relatively low positive rate of NAC involvement.

In our study, 6(50%) of patients with NAC involvement were ER-, while 7(58.3%) of patients with NAC involvement were PR- and HER+. A systematic review by Zhang et al. reported a higher rate of NI among ER- patients (1.189, 95% CI = 1.008--1.404) and PR- patients (1.515, 95% CI = 1.248--1.84). On the other hand, the pooled analysis of the same study with respect to HER status revealed a stronger association between having NI and being HER+ (RR = 1.760, 95% CI = 1.463--2.116) \[[@CR22]\]. Another study reported that HER overexpression was associated with NAC involvement (*p* = 0.0137), which supports our findings \[[@CR25]\]. Brachtel et al. have also reported that HER2 overexpression is associated with NAC involvement \[[@CR31]\]. HER positivity in patients with NAC involvement may be a potential indicator of the presence of Paget's disease. Pirozzi and his colleagues published different results regarding hormonal factors, as they found no significant differences between the groups described in this study regarding PR and ER status (*p* = 0.794 and 0.825, respectively) \[[@CR16]\].

Conclusion {#Sec12}
==========

The incidence of NAC involvement among patients with breast carcinoma who underwent mastectomy and axillary clearance was associated with certain important factors, such as the tumour size, the distance from the tumour site to the edge of the areola, lymph node metastasis, lymphovascular invasion, HER overexpression, and ER and PR negativity. Accordingly, NAC-preserving surgeries and NSM are oncologically safe procedures in well selected patients with tumors at stages 0--II, peripheral tumors far from the nipple, and with favourable pathological features.
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